Table 2.
RA | Non-RA | ||||
---|---|---|---|---|---|
Persistent | Resolving | Persistent | Resolving | p | |
N | 19 | 5 | 23 | 49 | |
Female, % | 58 | 60 | 35 | 41 | NS** |
Age, yrs* | 67 (59–74) | 56 (44–61) | 37 (25–58) | 41 (32–54) | p = 0.0003† RA persistent vs non-RA persistent p < 0.001 RA persistent vs non-RA resolving p < 0.01 |
Symptom duration, wks* | 6 (4–9) | 8 (5–12) | 7 (4–10) | 3 (2–7) | p = 0.001† Intergroup comparisons NS |
Initial CRP, mg/l * | 25 (18–41) | 19 (9–81) | 46 (24–95) | 23 (7–56) | NS† |
No. swollen joints* | 5 (2–7) | 5 (1–11) | 2 (1–3) | 2 (1–3) | p = 0.0005† RA persistent vs non-RA resolving p < 0.01 |
No. swollen joint areas* | 3 (2–4) | 5 (1–5) | 2 (1–3) | 1 (1–2.5) | p = 0.001† RA persistent vs non-RA resolving p < 0.01 RA resolving vs non-RA resolving p < 0.01 |
Results given as median (interquartile range) except for RA (Resolving), where median (range) are given.
Groups compared using chi-square test.
Groups compared using Kruskal-Wallis test, where the difference between groups was statistically significant at the 5% level, intergroup comparisons were performed using Dunn’s test. NS: not significant.